Synbiotics and Gut Microbiota Modulation in Type 2 Diabetes Mellitus: Mechanisms, Clinical Evidence, and Applications in Livestock-Derived Products
DOI:
https://doi.org/10.25077/alive.v3.n2.p195-207.2026Keywords:
synbiotic, gut microbiota, type 2 diabetes, short-chain fatty acids, fermented dairyAbstract
This review evaluates the scientific evidence on synbiotic interventions for modulating the gut microbiota as an adjuvant strategy in type 2 diabetes mellitus (T2DM), with a focus on the roles of short-chain fatty acids (SCFAs), intestinal barrier integrity, and inflammation, as well as their relevance for applications in livestock-derived products. The literature was searched up to 30 November 2025 using PubMed, ScienceDirect, and Google Scholar (publication years 2010–2025) with keywords related to synbiotics, gut microbiota, T2DM, probiotics, prebiotics, and SCFAs. The references considered included controlled clinical trials, preclinical animal studies, and relevant English-language review articles available in full text, which were then synthesized narratively. Dysbiosis in T2DM is generally characterized by a reduction in SCFA-producing bacteria and an increase in pro-inflammatory taxa, which are associated with increased intestinal permeability, lipopolysaccharide (LPS) endotoxemia, and low-grade inflammation that exacerbates insulin resistance. The clinical and preclinical evidence reviewed suggests that synbiotics may shift the gut microbial composition toward commensal SCFA-producing taxa, increase SCFA production, improve intestinal barrier function, reduce inflammatory markers, and improve glycemic outcomes. However, heterogeneity in strains, substrates, doses, intervention durations, and the reporting of microbiota/metabolite endpoints limits comparability across studies. Overall, synbiotics show potential as an adjuvant approach for T2DM through modulation of the microbiota, SCFA, intestinal barrier axis, and suppression of inflammation. The development of functional foods based on livestock-derived products is promising, but requires formulation standardization, more robustly designed controlled clinical trials, and evaluation of stability/viability during processing and storage.
Downloads
References
Arora, A., Behl, T., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Sanchez, E.S., & Bungau, S. (2021). Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. Life sciences, 273, 119311. https://doi.org/10.1016/j.lfs.2021.119311
Ban, Q., Cheng, J., Sun, X., Jiang, Y., Zhao, S., Song, X., & Guo, M. (2020). Effects of a synbiotic yogurt using monk fruit extract as sweetener on glucose regulation and gut microbiota in rats with type 2 diabetes mellitus. Journal of dairy science, 103(4), 2956-2968. https://doi.org/10.3168/jds.2019-17700
Camargo, A., Jimenez-Lucena, R., Alcala-Diaz, J. F., Rangel-Zuñiga, O. A., Garcia-Carpintero, S., Lopez-Moreno, J., Blanco-Rojo, R., Delgado-Lista, J., Perez-Martinez, P., van Ommen, B., Malagon, M. M., Ordovos, J. M., Perez-Jimenez, F., & Lopez-Miranda, J. (2019). Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: from the CORDIOPREV study. Clinical Nutrition, 38(2), 529-538. https://doi.org/10.1016/j.clnu.2018.03.016
Chakma, S., Acharjee, M. R., Tonni, I. J., Tabassum, F., Das, E., Islam, S., & Al Faruq, S. (2025). Probiotic Potential of Yogurt: Exploring Lactic Acid Bacteria for Health-Enhancing Benefits. Applied Food Research, 101383. https://doi.org/10.1016/j.afres.2025.101383
Chaudhary, P. P., Kaur, M., & Myles, I. A. (2024). Does “all disease begin in the gut”? The gut-organ cross talk in the microbiome. Applied Microbiology and Biotechnology, 108(1), 339. https://doi.org/10.1007/s00253-024-13180-9
Chong, S., Lin, M., Chong, D., Jensen, S., & Lau, N. S. (2025). A systematic review on gut microbiota in type 2 diabetes mellitus. Frontiers in endocrinology, 15, 1486793. https://doi.org/10.3389/fendo.2024.1486793
Colica, C., & Vecchio, I. (2025). Gut microbiota: origin or panacea for all ills? Part 1: Immune and Metabolic Diseases, Nutrition, and Microbiota-Based Interventions. Microbial Pathogenesis, 108213. https://doi.org/10.1016/j.micpath.2025.108213
Cox, A. J., Zhang, P., Bowden, D. W., Devereaux, B., Davoren, P. M., Cripps, A. W., & West, N. P. (2017). Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes & metabolism, 43(2), 163-166. https://doi.org/10.1016/j.diabet.2016.09.004
Dimeji, I. Y., & Ayodeji, A. S. (2025). Pharmacological Modulation of the Gut Microbiota and Endotoxaemia: A Next-Generation Approach to Treating Metabolic Syndrome. ASPET Discovery, 100010. https://doi.org/10.1016/j.aspetd.2025.100010
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell metabolism, 27(4), 740-756. https://doi.org/10.1016/j.cmet.2018.03.001
Fusco, W., Lorenzo, M. B., Cintoni, M., Porcari, S., Rinninella, E., Kaitsas, F., Lener, E., Mele, M. C., Gasbarrini, A., Collado, M. C., Cammarota, G., & Ianiro, G. (2023). Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients, 15(9), 2211. https://doi.org/10.3390/nu15092211
Gaike, A. H., Paul, D., Bhute, S., Dhotre, D. P., Pande, P., Upadhyaya, S., Reddy, Y., Sampath, R., Ghosh, D., Chandraprabha, D., Acharya, J., Banerjee, G., Sinkar, V. P., Ghaskadbi, S. S., & Shouche, Y. S. (2020). The gut microbial diversity of newly diagnosed diabetics but not of prediabetics is significantly different from that of healthy nondiabetics. Msystems, 5(2), 10-1128. https://doi.org/10.1128/msystems.00578-19
Ghafouri, A., Zarrati, M., Shidfar, F., Heydari, I., Shokouhi Shoormasti, R., & Eslami, O. (2019). Effect of synbiotic bread containing lactic acid on glycemic indicators, biomarkers of antioxidant status and inflammation in patients with type 2 diabetes: a randomized controlled trial. Diabetology & metabolic syndrome, 11(1), 103. https://doi.org/10.1186/s13098-019-0496-9
Jan, T., Negi, R., Sharma, B., Kumar, S., Singh, S., Rai, A. K., Shreaz, S., Rustagi, S., Chaudhary, N., Kaur, T., Kour, D., Sheikh, M. A., Kumar, K., Yadav, A. N., & Ahmed, N. (2024). Next generation probiotics for human health: An emerging perspective. Heliyon, 10(16), e35980. https://doi.org/10.1016/j.heliyon.2024.e35980
Kallassy, J., Gagnon, E., Rosenberg, D., Silbart, L. K., & McManus, S. A. (2023). Strains of Faecalibacterium prausnitzii and its extracts reduce blood glucose levels, percent HbA1c, and improve glucose tolerance without causing hypoglycemic side effects in diabetic and prediabetic mice. BMJ Open Diabetes Research & Care, 11(3). https://doi.org/10.1136/bmjdrc-2022-003101
Kanazawa, A., Aida, M., Yoshida, Y., Kaga, H., Katahira, T., Suzuki, L., Tamaki, S., Sato, J., Goto, H., Azuma, K., Shimizu, T., Takahashi, T., Yamashiro, Y., & Watada, H. (2021). Effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: a randomized controlled study. Nutrients, 13(2), 558. https://doi.org/10.3390/nu13020558
Kim, H. K., Rutten, N. B. M. M., Besseling-van Der Vaart, I., Niers, L. E. M., Choi, Y. H., Rijkers, G. T., & van Hemert, S. (2015). Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema. Beneficial microbes, 6(6), 783-790. https://doi.org/10.3920/bm2015.0056
Kumawat, V. S., & Kaur, G. (2019). Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications. European journal of pharmacology, 862, 172628. https://doi.org/10.1016/j.ejphar.2019.172628
Larsen, J. M. (2017). The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology, 151(4), 363-374. https://doi.org/10.1111/imm.12760
Ling, X., Linglong, P., Weixia, D., & Hong, W. (2016). Protective effects of bifidobacterium on intestinal barrier function in LPS-induced enterocyte barrier injury of Caco-2 monolayers and in a rat NEC model. PloS one, 11(8), e0161635. https://doi.org/10.1371/journal.pone.0161635
Liu, Y., Wang, J., & Wu, C. (2022). Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. Frontiers in nutrition, 8, 634897. https://doi.org/10.3389/fnut.2021.634897
Mafe, A. N., Edo, G. I., Majeed, O. S., Gaaz, T. S., Akpoghelie, P. O., Isoje, E. F., Igbuku, U. A., Owheruo, J. O., Opiti, R. A., Garba, Y., Essaghah, A. E. A., Ahmed, D. S., & Umar, H. (2025). A review on probiotics and dietary bioactives: Insights on metabolic well-being, gut microbiota, and inflammatory responses. Food Chemistry Advances, 6, 100919. https://doi.org/10.1016/j.focha.2025.100919
Malinowska, A. M., Majcher, M., Hooiveld, G. J., Przydatek, H., Szaban, M., Kurowiecka, A., & Schmidt, M. (2023). Experimental capacity of human fecal microbiota to degrade fiber and produce short-chain fatty acids is associated with diet quality and anthropometric parameters. The Journal of Nutrition, 153(10), 2827-2841. https://doi.org/10.1016/j.tjnut.2023.08.007
Melia, S., E. Purwati, S. N. Aritonang, dan M. Silaen. 2017. Characterization of the antimicrobial activity of lactic acid bacteria isolated from buffalo milk in West Sumatera (Indonesia) against Listeria monocytogenes. Pakistan Journal of Nutrition, 16(8), 645–650.
Mirjalili, M., Sharif, A. S., Sangouni, A. A., Emtiazi, H., & Mozaffari-Khosravi, H. (2023). Effect of probiotic yogurt consumption on glycemic control and lipid profile in patients with type 2 diabetes mellitus: A randomized controlled trial. Clinical nutrition ESPEN, 54, 144-149. https://doi.org/10.1016/j.clnesp.2023.01.014
Mohamadshahi, M., Veissi, M., Haidari, F., Javid, A. Z., Mohammadi, F., & Shirbeigi, E. (2014). Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences, 19(6), 531.
Moroti, C., Souza Magri, L. F., de Rezende Costa, M., Cavallini, D. C., & Sivieri, K. (2012). Effect of the consumption of a new synbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids in health and disease, 11(1), 29. https://doi.org/10.1186/1476-511x-11-29
Ostadrahimi, A., Taghizadeh, A., Mobasseri, M., Farrin, N., Payahoo, L., Gheshlaghi, Z. B., & Vahedjabbari, M. (2015). Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iranian journal of public health, 44(2), 228.
Patra, D., Banerjee, D., Ramprasad, P., Roy, S., Pal, D., & Dasgupta, S. (2023). Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes. Frontiers in molecular biosciences, 10, 1224982. https://doi.org/10.3389/fmolb.2023.1224982
Pushpanathan, P., Srikanth, P., Seshadri, K. G., Selvarajan, S., Pitani, R. S., Kumar, T. D., & Janarthanan, R. (2016). Gut microbiota in type 2 diabetes individuals and correlation with monocyte chemoattractant protein1 and interferon gamma from patients attending a tertiary care centre in Chennai, India. Indian journal of endocrinology and metabolism, 20(4), 523-530. https://doi.org/10.4103/2230-8210.183474
Ragupathi, N. D., Sethuvel, D. M., Inbanathan, F. Y., & Veeraraghavan, B. (2018). Accurate differentiation of Escherichia coli and Shigella serogroups: challenges and strategies. New microbes and new infections, 21, 58-62.
Reddy, K. V. C. (2021). Heart-gut axis: Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to prevent cardiovascular disease through gut microbiota. Medicine in Microecology, 7, 100033.
Saleem, A., Ikram, A., Dikareva, E., Lahtinen, E., Matharu, D., Pajari, A. M., Vos, W. M., Hasan, F., Salonen, A., & Jian, C. (2022). Unique Pakistani gut microbiota highlights population-specific microbiota signatures of type 2 diabetes mellitus. Gut Microbes, 14(1), 2142009. https://doi.org/10.1080/19490976.2022.2142009
Scheithauer, T. P., Rampanelli, E., Nieuwdorp, M., Vallance, B. A., Verchere, C. B., Van Raalte, D. H., & Herrema, H. (2020). Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Frontiers in immunology, 11, 571731. https://doi.org/10.3389/fimmu.2020.571731
Setayesh, A., Karimi, M., Karimi, M. A., Pirzad, S., Heydari, M., Asbaghi, O., Davoodi, S.H., & Larijani, B. (2025). Effects of Probiotic and Synbiotic Supplementation on Glycemic Indices in Adult Individuals with Prediabetes and Type 2 Diabetes Mellitus: A Grade-Assessed Systematic Review and Dose–Response Meta-analysis of RCTs. Probiotics and Antimicrobial Proteins, 1-24. https://doi.org/10.1007/s12602-025-10644-w
Shen, R., Chen, S., Lei, W., Shen, J., Lv, L., & Wei, T. (2023). Nonfood probiotic, prebiotic, and synbiotic use reduces all-cause and cardiovascular mortality risk in older adults: a population-based cohort study. The Journal of nutrition, health and aging, 27(5), 391-397. https://doi.org/10.1007/s12603-023-1921-1
Swanson, K. S., De Vos, W. M., Martens, E. C., Gilbert, J. A., Menon, R. S., Soto-Vaca, A., Hautvast, J., Meyer, P. D., Borewicz, K., Vaughan, E. E., & Slavin, J. L. (2020). Effect of fructans, prebiotics and fibres on the human gut microbiome assessed by 16S rRNA-based approaches: a review. Beneficial microbes, 11(2), 101-130. https://doi.org/10.3920/bm2019.0082
Tao, S., Li, L., Li, L., Liu, Y., Ren, Q., Shi, M., Liu, J., Jiang, J., Ma, H., Huang, Z., Xia, Z., Pan, J., Wei, T., Wan, Y., Li, P., Lan, T., Tang, X., Zeng, X., Lei, S., Tang, H., Ma, L., & Fu, P. (2019). Understanding the gut–kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition. Acta Diabetologica, 56(5), 581-592. https://doi.org/10.1007/s00592-019-01316-7
Tonucci, L. B., Dos Santos, K. M. O., de Oliveira, L. L., Ribeiro, S. M. R., & Martino, H. S. D. (2017). Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clinical nutrition, 36(1), 85-92. https://doi.org/10.1016/j.clnu.2015.11.011
Vallianou, N. G., Stratigou, T., & Tsagarakis, S. (2018). Microbiome and diabetes: Where are we now?. Diabetes research and clinical practice, 146, 111-118. https://doi.org/10.1016/j.diabres.2018.10.008
Wang, H., Gao, K., Wen, K., Allen, I. C., Li, G., Zhang, W., Kocher, J., Yang, X., Giri-Rachman, E., Li, G.H., Clark-Deener, S., & Yuan, L. (2016). Lactobacillus rhamnosus GG modulates innate signaling pathway and cytokine responses to rotavirus vaccine in intestinal mononuclear cells of gnotobiotic pigs transplanted with human gut microbiota. BMC microbiology, 16(1), 109. https://doi.org/10.1186/s12866-016-0727-2
Xiao, Y., Feng, Y., Zhao, J., Chen, W., & Lu, W. (2025). Achieving healthy aging through gut microbiota-directed dietary intervention: Focusing on microbial biomarkers and host mechanisms. Journal of Advanced Research, 68, 179-200. https://doi.org/10.1016/j.jare.2024.03.005
Xu, J., Liang, R., Zhang, W., Tian, K., Li, J., Chen, X., Yu, T., & Chen, Q. (2020). Faecalibacterium prausnitzii-derived microbial Anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. Journal of Diabetes, 12(3), 224-236. https://doi.org/10.1111/1753-0407.12986
Yang, J., Liu, Y., Liu, J., Zhang, X., Zhu, Y., Chen, Y., Gong, G., & Tao, M. (2025). Synbiotic formulation of fermented yak milk by lacticaseibacillus paracasei YT805 and inulin and its efficacy on gut microbiota modulation. LWT, 118185. https://doi.org/10.1016/j.lwt.2025.118185
Yang, X. Y., Yu, H., Fu, J., Guo, H. H., Han, P., Ma, S. R., Pan, L. B., Zhang, Z. W., Xu, H., Hu, J. C., Zhang, H. J., Bu, M. M., Zhang, X. F., Yang, W., Wang, J. Y., Jin, J. Y., Zhang, H. C., Li, D. R., Lu, J. Y., Lin, Y., Jiang, J. D., Tong, Q., & Wang, Y. (2022). Hydroxyurea ameliorates atherosclerosis in ApoE-/- mice by potentially modulating Niemann-Pick C1-like 1 protein through the gut microbiota. Theranostics, 12(18), 7775–7787.
Yao, B., He, J., Yin, X., Shi, Y., Wan, J., & Tian, Z. (2019). The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF-κB dependent mechanism in Caco-2 cells. Toxicology letters, 316, 109-118. https://doi.org/10.1016/j.toxlet.2019.08.024
Yarahmadi, A., Afkhami, H., Javadi, A., & Kashfi, M. (2024). Understanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review. Diabetology & Metabolic Syndrome, 16(1), 308. https://doi.org/10.1186/s13098-024-01561-z
Zhao, L., Lou, H., Peng, Y., Chen, S., Zhang, Y., & Li, X. (2019). Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine, 66(3), 526-537. https://doi.org/10.1007/s12020-019-02103-8
Zhao, X., Zhang, Y., Guo, R., Yu, W., Zhang, F., Wu, F., & Shang, J. (2020). The alteration in composition and function of gut microbiome in patients with type 2 diabetes. Journal of diabetes research, 2020(1), 8842651.
Zhu, C., Song, K., Shen, Z., Quan, Y., Tan, B., Luo, W., Wu, S., Tang, K., Yang, Z., & Wang, X. (2018). Roseburia intestinalis inhibits interleukin-17 excretion and promotes regulatory T cells differentiation in colitis. Molecular medicine reports, 17(6), 7567-7574.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Zaky Syahputra, Sri Melia, Indri Juliyarsi, Ade Sukma

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

